Jump to content
This site uses cookies. Continued use is acceptance of our Terms of Use and Privacy Policy. More Info... ×
  • Welcome to Celiac.com!

    You have found your celiac tribe! Join us and ask questions in our forum, share your story, and connect with others.




  • Celiac.com Sponsor (A1):



    Celiac.com Sponsor (A1-M):


  • Get Celiac.com Updates:
    Help Celiac.com:
    eNewsletter
    Donate
  • Record is Archived

    This article is now archived and is closed to further replies.

    Jefferson Adams
    Jefferson Adams

    Nestec Receives Patent for Method of Predicting Celiac Disease Risk

    Reviewed and edited by a celiac disease expert.

    Celiac.com 07/26/2013 - There are a number of highly specific and sensitive blood tests that can be used in diagnosing celiac disease; however histological examination of a biopsy taken by endoscopy remains the gold standard for celiac diagnosis.

    Photo: CC-- Alexandre DulaunoyHowever, not every patient wants to undergo an endoscopy, and many will happily undergo additional blood tests to avoid or delay endoscopy.

    Celiac.com Sponsor (A12):
    In an effort to help clinicians make accurate celiac diagnosis without endoscopy and biopsy, the company Nestec S.A. of Vevey, Switzerland, a research and testing subsidiary of Nestlé has obtained U.S. Patent No. 8,409,819, entitled "Methods to predict risk for celiac disease by detecting anti-flagellin antibody levels."

    The inventors have shown that a subset of at risk patients had elevated anti-CBir1 antibodies and that this correlated with HLA-DQ2.5 and HLA-DQ8 genotypes.

    The inventors showed that a group at risk patients have elevated anti-CBir1 antibodies that correlate with HLA-DQ2.5 and HLA-DQ8 genotypes.

    Their patent contains two independent claims, numbers 1 and 9, each of which describes a method to aid in predicting whether a patient who is EMA positive, or who has a relative with celiac disease, is at risk for developing celiac disease.

    Each method relies on the CBir1 flagellin antigen, specifically the N-terminal residues 1-147, to determine whether or not a sample from an at-risk patient contains anti-CBir1 flagellin antibodies.

    Flagellin is a part of what makes up bacterial flagella, the molecular mechanism that drives the propeller-like motion in bacteria. The inventors theorize that individuals at risk for celiac disease may have an aggressive immune response to resident bacterial proteins, in this case flagellin.

    This method for predicting celiac disease risk may help clinicians to diagnose patients who wish to avoid endoscopy, or who wish additional tests before doing so. The new patent also notes that the method might help to identify patients at risk of developing celiac disease before any symptoms are present.



    User Feedback

    Recommended Comments

    Guest celiacMom

    Posted

    Good article but as far as I know sensitivity to gut bacteria is NOT a a factor in celiac disease, never heard of it as a factor... I thought it was production of antibodies to an enzyme in the gut that digests gluten... I am confused.

    Link to comment
    Share on other sites


    Guest
    This is now closed for further comments

  • Get Celiac.com Updates:
    Help Celiac.com:
    Donate
  • About Me

    Jefferson Adams

    Jefferson Adams is Celiac.com's senior writer and Digital Content Director. He earned his B.A. and M.F.A. at Arizona State University. His articles, essays, poems, stories and book reviews have appeared in numerous magazines, journals, and websites, including North American Project, Antioch Review, Caliban, Mississippi Review, Slate, and more. He is the author of more than 2,500 articles on celiac disease. His university coursework includes studies in science, scientific methodology, biology, anatomy, physiology, medicine, logic, and advanced research. He previously devised health and medical content for Colgate, Dove, Pfizer, Sharecare, Walgreens, and more. Jefferson has spoken about celiac disease to the media, including an appearance on the KQED radio show Forum, and is the editor of numerous books, including "Cereal Killers" by Scott Adams and Ron Hoggan, Ed.D.

    >VIEW ALL ARTICLES BY JEFFERSON ADAMS

     


  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):





    Celiac.com Sponsors (A17-M):




  • Related Articles

    Scott Adams
    Currently, the Center for Celiac Research is involved in two critical areas:
    * Multi-Center Serological Screening Study to determine the prevalence of Celiac Disease in the United States; and
    * New Diagnostic Assay to develop a non-invasive diagnostic test for Celiac Disease.
    1) SEROLOGIC SCREENING STUDY
    We have tested 3,076 samples as part of the Multi-Center Serological Study for the prevalence of Celiac Disease in the United States. Our preliminary findings indicate that 6.8% of first-degree relatives and 4.7% of second-degree relatives of Celiacs test positive for the disease. These results are similar to those reported previously in Europe, suggesting that Celiac Disease is currently under-diagnosed in the United States.We are extremely encouraged by these...


    Scott Adams
    Celiac.com 12/31/2002 - Long time celiac and intestinal disease researcher Kenneth Fine, M.D. brought the benefits of his research discoveries, and his medical experience and knowledge to the public through the Internet at Open Original Shared Link, Open Original Shared Link, and through a nationwide commitment to lecturing celiac support groups at no charge. Now Dr. Fine has found a new way to serve gluten sensitive individuals and their support organizations: through music!
    Dr. Fine has been a singer-songwriter/guitar player for many years and recently recorded 25 of his original songs in a recording studio with professional studio musicians. These songs are now available on two CDs. After much thought and prayer about how to incorporate more music into his life and how...


    Jefferson Adams
    Celiac.com 07/23/2012 - At 2012 Digestive Diseases Week in San Diego, California, Alvine Pharmaceuticals, Inc. announced the publication of data from Phase 2A trial of its main celiac disease compound, ALV003.
    The results show that ALV003, orally administered to celiac disease patients on a gluten free diet, significantly reduces gluten-triggered intestinal mucosal damage.
    For the trial, 41 adults with clinically proven celiac disease who had followed a gluten-free diet for at least one year were randomly given ALV003 or a placebo each day for six weeks. During that time, they also received 2g of gluten in the form of bread crumbs.
    Participants received a small bowel biopsy prior to randomization and again, at the end of the six week challenge.
    The results showed that t...


    Jefferson Adams
    Celiac.com 04/24/2014 - Though some celiacs will tell you they’re content to remain gluten-free for life, being able to freely consume gluten is the dream of many a person with celiac disease.
    ImmusanT is one of the few companies working on an actual vaccine for celiac disease. Over the next few months, ImmusanT is likely to begin reporting data from two separate early-stage clinical trials for NexVax2, a celiac disease vaccine.
    That data will offer the first glimpse into the potential for ImmusanT to treat celiac disease, and into the viability of the company’s peptide immunotherapy platform.
    The current two studies are Phase 1b trials, designed to confirm the safety of NexVax2, and to find a range of potential doses for the company’s next trials. Success at this stage still...


  • Recent Activity

    1. - cristiana replied to djmu's topic in Related Issues & Disorders
      5

      Peripheral Neuropathy

    2. - Tlbaked13 replied to djmu's topic in Related Issues & Disorders
      5

      Peripheral Neuropathy

    3. - trents replied to djmu's topic in Related Issues & Disorders
      5

      Peripheral Neuropathy

    4. - shadycharacter replied to Linedancegal's topic in Introduce Yourself / Share Stuff
      5

      25 year biopsy confirmed/ate pizza with no ill effects?

    5. - Tlbaked13 replied to djmu's topic in Related Issues & Disorders
      5

      Peripheral Neuropathy


  • Celiac.com Sponsor (A19):



  • Member Statistics

    • Total Members
      120,467
    • Most Online (within 30 mins)
      7,748

    MorticiaCat
    Newest Member
    MorticiaCat
    Joined

  • Celiac.com Sponsor (A20):


  • Forum Statistics

    • Total Topics
      120.2k
    • Total Posts
      1m

  • Celiac.com Sponsor (A22):





  • Celiac.com Sponsor (A21):



  • Popular Now

    • Linedancegal
    • Hannah24
      7
    • jessiemariecar
    • Rhonda H
    • HayleyC123
  • Popular Articles

    • Scott Adams
    • Scott Adams
    • Scott Adams
    • Scott Adams
    • Scott Adams
  • Upcoming Events

×
×
  • Create New...